TISSUEBLUE by is a Prescription medication manufactured, distributed, or labeled by D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Pharmpur GmbH. Drug facts, warnings, and ingredients follow.
TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM). (1)
TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is supplied in 2.25 mL syringes filled to a volume of 0.5 mL. (3)
None (4)
Excessive staining: Excess TissueBlue 0.025% should be removed from the eye immediately after staining.
Use of the syringe: Make sure the plunger moves smoothly before injecting the solution. (5)
Adverse reactions that have been reported in procedures that included the use of TissueBlue 0.025% have often been associated with the surgical procedure. The complications include retinal (retinal break, tear, hemorrhage, and detachment and cataracts. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Dutch Ophthalnic, USA at 1-800-75-DUTCH or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch (6)
Revised: 12/2019
TissueBlue 0.025% is carefully injected into the Balanced Salt Solution (BSS)-filled vitreous cavity using a blunt cannula attached to the pre-filled syringe, without allowing the cannula to contact the retina or allowing TissueBlue to get under the retina. Sufficient staining is expected within a few seconds. Following staining, all excess dye should be removed from the vitreous cavity.
Risk Summary
There are no available data on the use of TissueBlue 0.025% in pregnant women to inform a drug associated risk. Systemic absorption of TissueBlue 0.025% in humans is expected to be negligible following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures. Due to the negligible systemic exposure, it is not expected that maternal use of TissueBlue 0.025% will result in fetal exposure to the drug.
Adequate animal reproduction studies were not conducted with TissueBlue 0.025%.
Risk Summary
No data are available regarding the presence of Brilliant Blue G in human milk after intraocular administration of TissueBlue 0.025%, or the effects on the breastfed infant or the effects on milk production. However, breastfeeding is not expected to result in exposure of the child to Brilliant Blue G due to the expected negligible systemic exposure of BBG in humans following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures.
TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a sterile solution of BBG (a dye). Each mL of TissueBlue 0.025% contains BBG 0.25 mg, Polyethylene Glycol 40mg and Buffered Sodium Chloride solution (8.20 mg of sodium chloride, 3.10 mg sodium phosphate dibasic dodecahydrate, 0.30 mg sodium phosphate monobasic dihydrate, water for injection). The pH range of TissueBlue 0.025% Solution is between 7.3 and 7.6.
The drug substance BBG has the chemical name Brilliant Blue G, a molecular weight of 854.02 and has the following chemical structure:
Molecular formula: C47H48N3NaO7S2
Studies to evaluate the potential for carcinogenicity or impairment of fertility of TissueBlue 0.025% have not been conducted.
Brilliant Blue G was not mutagenic in the Ames assay, the in vitro mouse lymphoma assay, or the in vivo rat micronucleus assay.
TissueBlue (Brilliant Blue G Ophthalmic Solution), 0.025% is supplied as 0.5 mL of Brilliant Blue G Ophthalmic Solution, 0.025% in a sterile, single-dose Luer Lok, 2.25 mL glass syringe, with a grey rubber plunger stopper and tip cap with polypropylene plunger rod in a pre-formed polypropylene blister pouch sealed with a Tyvek® lid.
NDC: 68803-722-05 (One 0.5 mL syringe)
NDC: 68803-722-25 (Carton of five 0.5 mL syringes)
TissueBlue
(Brilliant Blue G Ophthalmic Solution) 0.025%
Staining Solution for Ophthalmic Surgery
Protect from light, frost and moisture. Store at 15°C to 25°C (59°F to 77°F). Sterile.
Active ingredients/Ingrédient actif: Brilliant Blue G 0.025% Inactive ingredients/Ingrédients inactifs: Water for injection, Sodium chloride, Sodium phosphate dibasic dihydrate, Sodium phosphate monobasic dihydrate, Polyethylene Glycol.
NDC: 68803-722-05 (One 0.5 mL syringe)
NDC: 68803-722-25 (Carton of five 0.5 mL syringes)
TISSUEBLUE
brilliant blue g injection, solution |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
Labeler - D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. (407522184) |
Registrant - D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. (407522184) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Pharmpur GmbH | 340805167 | manufacture(68803-722) |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TISSUEBLUE 87870544 not registered Live/Pending |
D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. 2018-04-10 |